Elanco Animal Health Incorporated last reported quarterly results on Aug 5, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.4 billion (+10.2% year over year) and diluted EPS of $0.11. It usually reports 36–55 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 4, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 5, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–55 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1,368
+10.2%
|
54
+390.9%
|
0.11
+450.0%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1,371
+14.9%
|
57
-14.9%
|
0.11
-15.4%
|
|
Feb 24, 2026
55 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1,144
+12.2%
|
-276
-3350.0%
|
-0.57
-3466.5%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1,137
+10.4%
|
-34
-109.3%
|
-0.07
-109.6%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1,241
+4.8%
|
11
+122.0%
|
0.02
+120.0%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1,193
-1.0%
|
67
+109.4%
|
0.13
+116.7%
|
|
Feb 25, 2025
56 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
1,020
-1.4%
|
-8
+94.3%
|
-0.02
+94.4%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1,030
-3.6%
|
364
+133.2%
|
0.73
+132.9%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELAN (NYSE)
- Fiscal year ends
- December 31
- Headquarters
- Indianapolis, IN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1739104
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.